| Name | Title | Contact Details |
|---|
Devo, the cloud-native logging and security analytics company, empowers security and operations teams to maximize the value of all their data. Only the Devo platform delivers the powerful combination of real-time visibility, high-performance analytics, scalability, multitenancy, and low TCO crucial for monitoring and securing business operations as enterprises accelerate their shift to the cloud. Headquartered in Cambridge, Mass., Devo is backed by Insight Partners, Georgian, and Bessemer Venture Partners.
Seagull Software Systems is a Atlanta, GA-based company in the Software and Internet sector.
Evidian Systems is a New York, NY-based company in the Software and Internet sector.
Cogito enhances the emotional intelligence of phone professionals by applying behavioral science through artificial intelligence and machine learning. Cogito`s software evaluates hundreds of behavioral signals through voice to provide live conversation coaching for agents and a real-time measure of customer experience for every call. Cogito is helping the world`s most successful enterprises improve sales results, deliver amazing customer experiences, and enhance quality of care. Backed by OpenView Ventures, Romulus Capital and Salesforce Ventures, Cogito is headquartered in Boston, MA. At Cogito, we are united through the common goals of producing innovative technology, driving customer success, and helping people live more productive lives.
Exostar is the cloud platform of choice for secure enterprise and supply chain collaboration solutions and identity and access management expertise. Named a Cool Vendor by Gartner, we forge strong connections between people and technology and partner organizations. Over 125,000 organizations worldwide leverage Exostar to help them meet regulation compliance, such as DFAR and HIPAA, while reducing costs and fulfilling time-to-market objectives. Exostar`s various industry base includes customers such as Boeing, Rolls Royce, Lockheed Martin, BAE Systems, Raytheon, Merck, AstraZeneca, Charles River Laboratories, MedImmune and Barclays.